Clinical  	Clinical  	 JJ	B-NP
guideline  	guideline  	 NN	I-NP
recommendations  	recommendations  	 NNS	I-NP
for  	for  	 IN	I-NP
antipsychotic  	antipsychotic  	 JJ	I-NP
long-acting  	long-acting  	 JJ	I-NP
injections  	injections  	 NNS	I-NP
Long-acting  	Long-acting  	 JJ	I-NP
injections  	injections  	 NNS	I-NP
( 	( 	 -LRB-	O
LAIs 	LAIs 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
antipsychotic  	antipsychotic  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
were  	were  	 VBD	O
developed  	developed  	 VBN	O
over  	over  	 IN	O
40  	40  	 CD	O
years  	years  	 NNS	O
ago  	ago  	 RB	O
in  	in  	 IN	O
an  	an  	 DT	O
attempt  	attempt  	 NN	O
to  	to  	 TO	O
improve  	improve  	 VB	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
schizophrenia 	schizophrenia 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
review  	review  	 VB	O
existing  	existing  	 VBG	B-NP
guidelines  	guidelines  	 NNS	I-NP
concerning  	concerning  	 VBG	I-NP
antipsychotic  	antipsychotic  	 NNS	I-NP
use  	use  	 VBP	O
generally 	generally 	 RB	O
,  	,  	 ,	O
and  	and  	 CC	O
LAIs  	LAIs  	 JJ	B-NP
in  	in  	 IN	O
particular 	particular 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
how  	how  	 WRB	O
patients  	patients  	 NNS	O
might  	might  	 MD	O
be  	be  	 VB	O
identified  	identified  	 VBN	O
as  	as  	 IN	O
potential  	potential  	 JJ	B-NP
candidates  	candidates  	 NNS	I-NP
for  	for  	 IN	I-NP
LAI  	LAI  	 NNP	I-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
Literature  	Literature  	 NN	B-NP
review 	review 	 NN	I-NP
.  	.  	 .	O
Currently  	Currently  	 RB	O
several  	several  	 JJ	O
first-generation  	first-generation  	 JJ	B-NP
and  	and  	 CC	O
one  	one  	 CD	O
second-generation  	second-generation  	 JJ	B-NP
antipsychotic  	antipsychotic  	 JJ	I-NP
LAIs  	LAIs  	 NNS	I-NP
are  	are  	 VBP	O
available 	available 	 JJ	O
,  	,  	 ,	O
with  	with  	 IN	O
others  	others  	 NNS	O
under  	under  	 IN	O
development 	development 	 NN	O
.  	.  	 .	O
Although  	Although  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
LAIs  	LAIs  	 NNP	B-NP
is  	is  	 VBZ	O
widespread  	widespread  	 JJ	O
around  	around  	 IN	O
the  	the  	 DT	O
world 	world 	 NN	O
,  	,  	 ,	O
patterns  	patterns  	 NNS	O
of  	of  	 IN	O
use  	use  	 NN	O
vary  	vary  	 VBP	O
widely 	widely 	 RB	O
.  	.  	 .	O
Important  	Important  	 JJ	B-NP
considerations  	considerations  	 NNS	I-NP
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
LAIs  	LAIs  	 NNS	B-NP
include  	include  	 VBP	O
the  	the  	 DT	O
indications  	indications  	 NNS	O
for  	for  	 IN	O
long-term  	long-term  	 JJ	O
pharmacotherapy  	pharmacotherapy  	 NN	B-NP
in  	in  	 IN	O
schizophrenia  	schizophrenia  	 NN	O
in  	in  	 IN	O
general 	general 	 JJ	O
,  	,  	 ,	O
the  	the  	 DT	O
indications  	indications  	 NNS	O
for  	for  	 IN	O
LAIs 	LAIs 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
risks  	risks  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
LAIs 	LAIs 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
need  	need  	 NN	O
to  	to  	 TO	O
update  	update  	 VB	O
guidelines  	guidelines  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
issue  	issue  	 NN	O
of  	of  	 IN	O
cost 	cost 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
injections  	injections  	 NN	O
in  	in  	 IN	O
first-episode  	first-episode  	 JJ	B-NP
psychosis  	psychosis  	 NN	I-NP
and  	and  	 CC	O
treatment-refractory  	treatment-refractory  	 JJ	B-NP
schizophrenia  	schizophrenia  	 NN	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
currently  	currently  	 RB	O
a  	a  	 DT	O
focus  	focus  	 NN	O
of  	of  	 IN	O
recommendations 	recommendations 	 NNS	B-NP
,  	,  	 ,	O
but  	but  	 CC	O
should  	should  	 MD	O
be  	be  	 VB	O
considered 	considered 	 VBN	O
.  	.  	 .	O
Long-acting  	Long-acting  	 JJ	B-NP
injections  	injections  	 NNS	I-NP
remain  	remain  	 VBP	O
an  	an  	 DT	O
underutilised  	underutilised  	 JJ	B-NP
option  	option  	 NN	I-NP
in  	in  	 IN	O
many  	many  	 JJ	O
countries  	countries  	 NNS	O
despite  	despite  	 IN	O
frequent  	frequent  	 JJ	O
non-adherence  	non-adherence  	 NN	B-NP
with  	with  	 IN	O
oral  	oral  	 JJ	B-NP
medication  	medication  	 NN	I-NP
and  	and  	 CC	O
subsequent  	subsequent  	 JJ	O
relapse 	relapse 	 NN	O
.  	.  	 .	O
